Hereditary Cancer Syndromes > BRIP1, BARD1, RAD51C, RAD51D
CANCER
GENETIC CANCER RISK
Ovarian
High Risk
CANCER TYPE
PROCEDURE
AGE TO BEGIN
RISK FOR GENERAL POPULATION
Female Breast
To age 80
20%
10.2%
CANCER TYPE
PROCEDURE
AGE TO BEGIN
RISK FOR GENERAL POPULATION
Ovarian
To age 80
5.8%
1.0%
CANCER TYPE
PROCEDURE
AGE TO BEGIN
RISK FOR GENERAL POPULATION *
Ovarian
To age 50
1.0%
0.2%
6.7%
1.0%
To age 80
CANCER TYPE
PROCEDURE
AGE TO BEGIN
RISK FOR GENERAL POPULATION *
Ovarian
To age 50
2.3%
0.2%
To age 80
14.8%
1.0%
CANCER TYPE
PROCEDURE
AGE TO BEGIN
RISK FOR GENERAL POPULATION *
Female Breast
Currently there are no specific medical management guidelines for breast cancer risk in mutation carriers. However, the increased risk for breast cancer warrants consideration of individualized breast cancer risk-reduction strategies, such as the modification of standard population screening recommendations by starting screening at younger ages, performing screenings at greater frequency, and utilizing more sensitive technologies such as breast MRI.
Individualized
NA
CANCER TYPE
PROCEDURE
AGE TO BEGIN
RISK FOR GENERAL POPULATION *
Ovarian
Consider bilateral salpingo-oophorectomy (BSO).
45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age
NA
Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk-reduction strategies using other currently available options, such as surveillance and the use of risk-reducing agents.
Individualized
NA
CANCER TYPE
PROCEDURE
AGE TO BEGIN
FREQUENCY
Ovarian
Consider bilateral salpingo-oophorectomy (BSO).
45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age
NA
Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk-reduction strategies using other currently available options, such as surveillance and the use of risk-reducing agents.
Individualized
NA
CANCER TYPE
PROCEDURE
AGE TO BEGIN
FREQUENCY
Ovarian
Consider bilateral salpingo-oophorectomy (BSO).
45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age
NA
Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk-reduction strategies using other currently available options, such as surveillance and the use of risk-reducing agents.
Individualized
NA
